![Inhaled third-generation vaccine developed by CanSinoBIO proves higher protection as booster against Omicron - Global Times Inhaled third-generation vaccine developed by CanSinoBIO proves higher protection as booster against Omicron - Global Times](https://www.globaltimes.cn/Portals/0/attachment/2022/2022-03-14/e4234ce8-5dee-4e2d-b07a-ff0ee8a1853f.jpeg)
Inhaled third-generation vaccine developed by CanSinoBIO proves higher protection as booster against Omicron - Global Times
![Challenges in ensuring global access to COVID-19 vaccines: production, affordability, allocation, and deployment - The Lancet Challenges in ensuring global access to COVID-19 vaccines: production, affordability, allocation, and deployment - The Lancet](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/asset/0380ef55-ff96-471d-8d32-f9f880cfa9ba/gr1.jpg)
Challenges in ensuring global access to COVID-19 vaccines: production, affordability, allocation, and deployment - The Lancet
PLOS Neglected Tropical Diseases: A third generation vaccine for human visceral leishmaniasis and post kala azar dermal leishmaniasis: First-in-human trial of ChAd63-KH
![DNA vaccine: Methods and mechanisms Soltani S, Farahani A, Dastranj M, Momenifar N, Mohajeri P, Emamie AD - Adv Hum Biol DNA vaccine: Methods and mechanisms Soltani S, Farahani A, Dastranj M, Momenifar N, Mohajeri P, Emamie AD - Adv Hum Biol](https://www.aihbonline.com/articles/2018/8/3/images/AdvHumBiol_2018_8_3_132_241934_t2.jpg)
DNA vaccine: Methods and mechanisms Soltani S, Farahani A, Dastranj M, Momenifar N, Mohajeri P, Emamie AD - Adv Hum Biol
![Nanoparticulate carrier(s): an emerging paradigm in new generation vaccine development - ScienceDirect Nanoparticulate carrier(s): an emerging paradigm in new generation vaccine development - ScienceDirect](https://ars.els-cdn.com/content/image/3-s2.0-B9780323461436000178-f17-03-9780323461436.jpg)
Nanoparticulate carrier(s): an emerging paradigm in new generation vaccine development - ScienceDirect
![Possibilities and challenges for developing a successful vaccine for leishmaniasis | Parasites & Vectors | Full Text Possibilities and challenges for developing a successful vaccine for leishmaniasis | Parasites & Vectors | Full Text](https://media.springernature.com/full/springer-static/image/art%3A10.1186%2Fs13071-016-1553-y/MediaObjects/13071_2016_1553_Fig1_HTML.gif)
Possibilities and challenges for developing a successful vaccine for leishmaniasis | Parasites & Vectors | Full Text
PLOS Neglected Tropical Diseases: A third generation vaccine for human visceral leishmaniasis and post kala azar dermal leishmaniasis: First-in-human trial of ChAd63-KH
![High seroprotection rates achieved with two doses of Sci-B-Vac, a third- generation hepatitis B vaccine containing Pre-S1, Pre-S2, and S antigens - VBI Vaccines High seroprotection rates achieved with two doses of Sci-B-Vac, a third- generation hepatitis B vaccine containing Pre-S1, Pre-S2, and S antigens - VBI Vaccines](https://www.vbivaccines.com/wp-content/uploads/2021/06/VBIV-EASL-2019-Poster_v2.png)